^
BIOMARKER:

RANBP2-ALK rearrangement + TNFRSF8 expression

i
Other names: RANBP2, RAN Binding Protein 2, NUP358, Acute Necrotizing Encephalopathy 1 (Autosomal Dominant), Nuclear Pore Complex Protein Nup358, E3 SUMO-Protein Ligase RanBP2, Ran-Binding Protein 2, 358 KDa Nucleoporin, Nucleoporin Nup358, Nucleoporin 358, ADANE, P270, E3 SUMO-Protein Transferase RanBP2, Transformation-Related Protein 2, RanBP2, IIAE3, ANE1, TRP1, TRP2, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Entrez ID:
News
Twitter
Trials
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
ceritinib + brentuximab vedotin
Sensitive: D – Preclinical
RANBP2-ALK rearrangement + TNFRSF8 expression
Fibrosarcoma
crizotinib + brentuximab vedotin
Sensitive: D – Preclinical
RANBP2-ALK rearrangement + TNFRSF8 expression
Sarcoma
brentuximab vedotin
Resistant: D – Preclinical